Lilly Looks To Emgality Access, Injector And Data To Differentiate Its CGRP Inhibitor

The three US FDA-approved anti-CGRP antibodies for migraine prevention have similar efficacy and matching prices, but Lilly thinks access to Emgality – including through value-based arrangements – along with the biologic's ease of use and headache-free data will differentiate the product.